Atossa Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $23.718 million for the nine months ended September 30, 2026, with cash and cash equivalents of $20.574 million at quarter end.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $20.574 million as of September 30, 2026, down from $41.299 million at December 31, 2025.
  • Nine-month net loss: The company reported a net loss of $23.718 million for the nine months ended September 30, 2026, compared to $23.833 million for the same period in 2025.
  • Third-quarter net loss: Net loss for the three months ended September 30, 2026 was $5.638 million, compared to $8.692 million in the prior-year quarter.
  • Operating cash burn: Net cash used in operating activities for the nine months ended September 30, 2026 was $24.745 million.
  • Capital raised: The company raised $4.500 million through a registered direct offering and $21 thousand net through its ATM program during the nine months ended September 30, 2026.
  • Shares outstanding: As of November 2, 2026, the registrant had 9,979,298 shares of common stock outstanding at $0.18 par value per share.
  • Accumulated deficit: The accumulated deficit reached $270.280 million as of September 30, 2026, up from $246.562 million at December 31, 2025.

Atossa Therapeutics Financial Position and Operations for the Quarter Ended September 30, 2026

According to the filing, Atossa Therapeutics (NASDAQ:ATOS) reported total assets of $26.448 million as of September 30, 2026, compared to $47.608 million at December 31, 2025. Total stockholders' equity declined to $21.739 million from $39.353 million over the same period, reflecting ongoing operating losses and cash usage. Total current liabilities were $4.709 million at quarter end, down from $8.255 million at year-end 2025, with accounts payable falling from $4.293 million to $1.501 million.

For the three months ended September 30, 2026, the company reported total operating expenses of $5.899 million, comprised of $3.378 million in research and development costs and $2.521 million in general and administrative expenses, according to the filing. This compares to total operating expenses of $9.251 million in the same quarter of 2025. Interest income for the third quarter of 2026 was $209 thousand, down from $570 thousand in the prior-year quarter. The net loss per share, basic and diluted, was $(0.56) for the three months ended September 30, 2026, against $(1.01) for the same quarter in 2025.

The filing also disclosed that during the second quarter of 2026, Atossa issued 1,363,637 shares of common stock through a registered direct offering, raising $4.500 million gross, with $501 thousand in associated issuance costs. An additional 4,300 shares were issued under the company's ATM program, generating $21 thousand net of issuance costs. Stock-based compensation totaled $2.084 million for the nine months ended September 30, 2026, per the filing. Prepaid materials stood at $3.014 million and other assets at $1.267 million as of September 30, 2026.

What Was Disclosed

Atossa Therapeutics filed its 10-Q for the quarterly period ended September 30, 2026, reporting a nine-month net loss of $23.718 million, cash of $20.574 million, total assets of $26.448 million, and an accumulated deficit of $270.280 million, along with details of a registered direct offering completed during the period.